Search

Your search keyword '"Lichtenstein, Gary R"' showing total 176 results
Start Over Author "Lichtenstein, Gary R" Publication Year Range Last 3 years
176 results on '"Lichtenstein, Gary R"'

1. Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel

Author

Shen, Bo, Abreu, Maria T., Cohen, Erica R., Farraye, Francis A., Fischer, Monika, Feuerstadt, Paul, Kapur, Saurabh, Ko, Huaibin M., Kochhar, Gursimran S., Liu, Xiuli, Mahadevan, Uma, McBride, Deborah L., Navaneethan, Udayakumar, Regueiro, Miguel, Ritter, Tim, Sharma, Prateek, and Lichtenstein, Gary R.

Published
2025
Full Text
View/download PDF

2. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Author

Abrahamovych, Orest, Abu-farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Al Kharrat, Houssam, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico, Armuzzi, Alessandro, Ashida, Toshifumi, Augustyn, Monika, Aumais, Guy, Azum, Martín, Baert, Filip, Balaz, Jozef, Balderramo, Domingo, Begun, Jakob, Berova, Temenuzhka, Billiauws, Lore, Blanco, Antonio, Bortlik, Martin, Bossa, Fabrizio, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chachu, Karen, Chamouard, Patrick, Chen, Chunxiao, Chen, Yan, Chen, Baili, Chen, Dongfeng, Chen, Hong, Chen, Youxiang, Chen, Chou-chen, Cheon, Jaehee, Chen, Minhu, Chiu, Cheng-tang, Choi, Changhwan, Chow, Elizabeth, Cicala, Michele, Cintra, Aderson, Danilkiewicz, Wit, Datsenko, Olena, De Hertogh, Gert, De María, Julio, Del Valle Torrealba Medina, Leyanira, Deliang, Liu, Desreumaux, Pierre, Dewint, Pieter, Ding, Shigang, Doherty, Glen, Draganova, Raina, Dutré, Joris, Duvall, George, Egan, Laurence, Fahed, Julien, Fechner, Lars, Fedurco, Miroslav, Ferhat Celik, Aykut, Fernandez, Juan, Filip, Rafal, Fishman, Sigal, Flores, Cristina, Fogel, Ronald, Fowler, Sharyle, Francesconi, Carlos, Fujii, Toshimitsu, Fujiya, Mikihiro, Fukata, Masayuki, Fukuhara, Seiichiro, Furumoto, Yohei, G.Kiss, Gyula, Gachowski, Waldemar, Gao, Xiang, Gasbarrini, Antonio, Gawdis-wojnarska, Beata, Gaya, Daniel, Geccherle, Andrea, Gilletta De Saint Joseph, Cyrielle, Gimenez, Edgardo, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Gonzales, Chad, Gonzalez, Raquel, Gonzalez Segura, Gaston Julian, Gridnyev, Oleksiy, Gu, Fang, Gupta, Nitin, Gyokeres, Tibor, Haines, Melissa, Hebuterne, Xavier, Hedin, Charlotte, Hellstrom, Per, Hilmi, Ida Normiha, Hirai, Fumihito, Hisabe, Takashi, Hlavaty, Tibor, Hoentjen, Frank, Holtmann, Gerald, Horiki, Noriyuki, Horny, Ivo, Horvat, Gyula, Horvath, Frantisek, Hoshi, Namiko, Hosomi, Shuhei, Hospodarskyy, Ihor, Hou, Xiaohua, Hrdlicka, Ludek, Hu, Naizhong, Huang, Vivian, Huang, Caibin, Inaba, Tomoki, Ishiguro, Yoh, Ishihara, Shunji, Ishikawa, Takeshi, Iskandar, Heba, Israeli, Eran, Itaba, Soichi, Ivanishyn, Olha, Izbéki, Ferenc, Jain, Animesh, Jairath, Vipul, Jang, Byung Ik, Jiang, Chunmeng, Jones, Michael, Kagaya, Takashi, Kalimullina, Dilara, Karakina, Marina, Karatas, Ali, Kashimura, Hiroshi, Keret, Dan, Khovaeva, Yaroslava, Kierkus, Jaroslaw, Kim, Taeoh, Kim, Youngho, Kim, Hyo Jong, Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-gembala, Iwona, Kojima, Yuichiro, Koo, Ja Seol, Kopon, Adam, Kopp, James, Koyama, Fumikazu, Koynarski, Vasil, Kravchenko, Tetiana, Kudo, Masatoshi, Kusunoki, Ryusaku, Kwon, Kwangan, Laclav, Martin, Lago, Paula, Laharie, David, Lasa, Juan, Lateef, Syed, Latinovic Radakovic, Tatjana, Lee, Kang Moon, Leszczyszyn, Jaroslaw, Li, Yan, Liu, Mei, Liu, Eashen, Lobaton Ortega, Triana, Lopatin, Denis, Lopes, Susana, Lovric Jovanovic, Mileva, Lubini, Marcio, Lukas, Milan, Maaser, Christian, Machytka, Evzen, Maemoto, Atsuo, Magro, Fernando, Marcet, Jorge, Marini, Eduardo, Marusawa, Hiroyuki, Matous, Jan, Matsumoto, Takayuki, Mendu, Shoba, Miao, Yinglei, Mihaly, Emese, Miheller, Pal, Ministro, Paula, Miyabayashi, Hideharu, Mohl, Wolfgang, Molnar, Martin, Moore, Gregory, Moran Faienzo, Gabriela, Morral, Eugeni Domenech, Motoya, Satoshi, Murali, Narayanachar, Mustaffa, Nazri Mohamad, Naem, Mohamed, Nakai, Katsuhiko, Nakajima, Koichi, Nakamoto, Yasunari, Nakamura, Masanao, Nancey, Stephane, Navaneethan, Udayakumar, Nawawi, Khairul Najmi Muhammad, Ninomiya, Tomoyuki, Novak, Janos, Oki, Motoji, Oliveira Santana, Genoile, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Parente, Jose Miguel, Patel, Kamal, Patel, Bhaktasharan, Pedersen, Peder, Petroniene, Rima, Petrov, Asen, Petrova, Elina, Piquet, Marie-astrid, Pokrotnieks, Juris, Poroshina, Elena, Portela, Francisco, Pruthi, Jatinder S., Prystupa, Lyudmila, Pukitis, Aldis, Qiu, Yun, Rafalsky, Vladimir, Rainis, Tova, Ramos Junior, Odery, Rashid, Mohammed, Rayyan, Yasser, Reshetko, Olga, Ribeiro, Tarsila, Rivero, Montserrat, Roblin, Xavier, Romatowski, Jacek, Rowbotham, David, Ruffinengo, Orlando Enrique, Rydzewska-wyszkowska, Grazyna, Sablin, Oleg, Sai, Souken, Saibeni, Simone, Said, Rosaida Hj. Md., Sakuraba, Hirotake, Samaan, Mark, Sandborn, William, Saruta, Masayuki, Sauk, Jenny, Savarino, Edoardo Vincenzo, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Seksik, Philippe, Senturk, Omer, Shelton, Edward, Shimizu, Masahito, Shin, Sungjae, Shukla, Richa, Sigal, Michael, Silva Junior, Roberto, Simoes Neto, Joaquim, Siroky Jr., Milan, Smajstrla, Vit, Smid, Vaclav, Smiley, Sarah, Soledad Brunatto, Luciana, Stanislavchuk, Mykola, Stokesberry, David, Stone, Christian, Suiter, Daniel, Suzuki, Takayoshi, Svorcan, Petar, Takagi, Sho, Takagi, Tomohisa, Takamura, Masaaki, Takayama, Tetsuji, Takeuchi, Ken, Tanaka, Akihito, Tanaka, Hiroki, Tanash, Omar, Tang, Wen, Tankova, Ludmila, Teixeira Campos, Luciana, Thin, Lena, Tkachev, Alexander, Tolmanis, Ivars, Tsarynna, Nataliia, Tsonev, Nikolay, Tulassay, Zsolt, Ueo, Tetsuya, Unal, Nalan, Valuyskikh, Ekaterina, Van Dop, Willemijn, Vasilevskaya, Olga, Venugopal, Kannan, Verstockt, Bram, Viamonte, Manuel, Vyshyvanyuk, Vira, Wang, Bangmao, Wang, Xiaoyan, Wang, Jiangbin, Wang, Yufang, Wei, Shu-chen, Weisshof, Roni, Wisam, Sbeit, Wojcik, Katarzyna, Yakovlev, Alexey, Yasuda, Hiroshi, Ye, Byongduk, Yen, Hsu-heng, Yilmaz, Hasan, Yokoyama, Yoko, Yoon, Hyuk, Yoshida, Takeshi, Yurkiv, Andriy, Zaha, Osamu, Zaltman, Cyrla, Zhan, Qiang, Zhang, Hongjie, Zhang, Shutian, Zhu, Lanxiang, Zou, Duowu, Zou, Xiaoping, Zureikat, Firas, Rubin, David T, Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, and Dignass, Axel

Published
2025
Full Text
View/download PDF

7. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Author

Abrahamovych, Orest, Afanasieva, Halyna, Aitova, Lilia, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Augustyn, Monika, Balestrieri, Paola, Begun, Jakob, Brunatto, Luciana, Bulgheroni, Diego, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chen, Baili, Chen, Chou-Chen, Chen, Chou-Pin, Chiu, Cheng-Tang, Choi, Chang Hwan, Cicala, Michele, Datsenko, Olena, Dewint, Pieter, Domenech, Eugeni, Dutré, Joris, Duvall, George, Fernandez, Juan, Filip, Rafal, Fogel, Ronald, Fowler, Sharyle, Fujii, Toshimitsu, Fukata, Masayuki, Furumoto, Yohei, Gasbarrini, Antonio, Gawdis-Wojnarska, Beata, Gilletta, Cyrielle, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Segura, Gaston Gonzalez, Gridnyev, Oleksii, Gyokeres, Tibor, Hébuterne, Xavier, Hedin, Charlotte, Hellström, Per, Hilmi, Ida Normiha, Horný, Ivo, Horvat, Gyula, Hoshi, Namiko, Hrdlicka, Ludek, Ishihara, Shunji, Ivanishyn, Olha, Jang, Byung Ik, Junior, Odery, Kagaya, Takashi, Kanmura, Shuji, Karakina, Marina, Katsuhiko, Nakai, Kierkus, Jaroslaw, Kim, Hyo Jong, Kim, Tae-Oh, Kim, Young-Ho, Kiss, Gyula G., Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-Gembala, Iwona, Koo, Ja Seol, Kopon, Adam, Kravchenko, Tetiana, Kudo, Masatoshi, Kwon, Kwang An, Lago, Paula, Laharie, David, Lawrance, Ian, Leszczyszyn, Jaroslaw, Li, Yan, Lukas, Milan, Maaser, Christian, Maemoto, Atsuo, Marusawa, Hiroyuki, McBride, Matthew, Mendu, Shoba, Miheller, Pal, Miyabayashi, Hideharu, Mohl, Wolfgang, Moore, Gregory, Motoya, Satoshi, Murali, Narayanachar, Naem, Mohammed, Nakajima, Koichi, Nakamoto, Yasunari, Nancey, Stéphane, Neto, Joaquim, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Patel, Bhaktasharan, Patel, Kamal, Petrova, Elina, Poroshina, Elena, Portela, Francisco, Prystupa, Lyudmyla, Rivero, Monserrat, Roblin, Xavier, Romatowski, Jacek, Rydzewska, Grazyna, Saibeni, Simone, Sakuraba, Hirotake, Samaan, Mark, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Shin, Sung Jae, Stanislavchuk, Mykola, Stokesberry, David, Suzuki, Takayoshi, Taguchi, Hiroki, Tankova, Lyudmila, Thin, Lena, Tkachev, Alexander, Torrealba, Leyanira, Tsarynna, Nataliia, Tulassay, Zsolt, Ueo, Tetsuya, Valuyskikh, Ekaterina, Vasilevskaya, Olga, Viamonte, Manuel, Wei, Shu-Chen, Weisshof, Roni, Wojcik, Katarzyna, Ye, Byong Duk, Yen, Hsu-Heng, Yoon, Hyuk, Yoshida, Kosuke, Yurkiv, Andriy, Zaha, Osamu, Zhan, Qiang, Peyrin-Biroulet, Laurent, Allegretti, Jessica R., Rubin, David T., Bressler, Brian, Germinaro, Matthew, Huang, Kuan-Hsiang (Gary), Shipitofsky, Nicole, Zhang, Hongyan, Wilson, Rebbecca, Han, Chenglong, Feagan, Brian G., Sandborn, William J., Panés, Julian, Hisamatsu, Tadakazu, Lichtenstein, Gary R., Sands, Bruce E., and Dignass, Axel

Published
2023
Full Text
View/download PDF

9. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Author

Rubin, David T, Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, Dignass, Axel, Abrahamovych, Orest, Abu-farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Al Kharrat, Houssam, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico, Armuzzi, Alessandro, Ashida, Toshifumi, Augustyn, Monika, Aumais, Guy, Azum, Martín, Baert, Filip, Balaz, Jozef, Balderramo, Domingo, Begun, Jakob, Berova, Temenuzhka, Billiauws, Lore, Blanco, Antonio, Bortlik, Martin, Bossa, Fabrizio, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chachu, Karen, Chamouard, Patrick, Chen, Chunxiao, Chen, Yan, Chen, Baili, Chen, Dongfeng, Chen, Hong, Chen, Youxiang, Chen, Chou-chen, Cheon, Jaehee, Chen, Minhu, Chiu, Cheng-tang, Choi, Changhwan, Chow, Elizabeth, Cicala, Michele, Cintra, Aderson, Danilkiewicz, Wit, Datsenko, Olena, De Hertogh, Gert, De María, Julio, Del Valle Torrealba Medina, Leyanira, Deliang, Liu, Desreumaux, Pierre, Dewint, Pieter, Ding, Shigang, Doherty, Glen, Draganova, Raina, Dutré, Joris, Duvall, George, Egan, Laurence, Fahed, Julien, Fechner, Lars, Fedurco, Miroslav, Ferhat Celik, Aykut, Fernandez, Juan, Filip, Rafal, Fishman, Sigal, Flores, Cristina, Fogel, Ronald, Fowler, Sharyle, Francesconi, Carlos, Fujii, Toshimitsu, Fujiya, Mikihiro, Fukata, Masayuki, Fukuhara, Seiichiro, Furumoto, Yohei, G.Kiss, Gyula, Gachowski, Waldemar, Gao, Xiang, Gasbarrini, Antonio, Gawdis-wojnarska, Beata, Gaya, Daniel, Geccherle, Andrea, Gilletta De Saint Joseph, Cyrielle, Gimenez, Edgardo, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Gonzales, Chad, Gonzalez, Raquel, Gonzalez Segura, Gaston Julian, Gridnyev, Oleksiy, Gu, Fang, Gupta, Nitin, Gyokeres, Tibor, Haines, Melissa, Hebuterne, Xavier, Hedin, Charlotte, Hellstrom, Per, Hilmi, Ida Normiha, Hirai, Fumihito, Hisabe, Takashi, Hlavaty, Tibor, Hoentjen, Frank, Holtmann, Gerald, Horiki, Noriyuki, Horny, Ivo, Horvat, Gyula, Horvath, Frantisek, Hoshi, Namiko, Hosomi, Shuhei, Hospodarskyy, Ihor, Hou, Xiaohua, Hrdlicka, Ludek, Hu, Naizhong, Huang, Vivian, Huang, Caibin, Inaba, Tomoki, Ishiguro, Yoh, Ishihara, Shunji, Ishikawa, Takeshi, Iskandar, Heba, Israeli, Eran, Itaba, Soichi, Ivanishyn, Olha, Izbéki, Ferenc, Jain, Animesh, Jairath, Vipul, Jang, Byung Ik, Jiang, Chunmeng, Jones, Michael, Kagaya, Takashi, Kalimullina, Dilara, Karakina, Marina, Karatas, Ali, Kashimura, Hiroshi, Keret, Dan, Khovaeva, Yaroslava, Kierkus, Jaroslaw, Kim, Taeoh, Kim, Youngho, Kim, Hyo Jong, Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-gembala, Iwona, Kojima, Yuichiro, Koo, Ja Seol, Kopon, Adam, Kopp, James, Koyama, Fumikazu, Koynarski, Vasil, Kravchenko, Tetiana, Kudo, Masatoshi, Kusunoki, Ryusaku, Kwon, Kwangan, Laclav, Martin, Lago, Paula, Laharie, David, Lasa, Juan, Lateef, Syed, Latinovic Radakovic, Tatjana, Lee, Kang Moon, Leszczyszyn, Jaroslaw, Li, Yan, Liu, Mei, Liu, Eashen, Lobaton Ortega, Triana, Lopatin, Denis, Lopes, Susana, Lovric Jovanovic, Mileva, Lubini, Marcio, Lukas, Milan, Maaser, Christian, Machytka, Evzen, Maemoto, Atsuo, Magro, Fernando, Marcet, Jorge, Marini, Eduardo, Marusawa, Hiroyuki, Matous, Jan, Matsumoto, Takayuki, Mendu, Shoba, Miao, Yinglei, Mihaly, Emese, Miheller, Pal, Ministro, Paula, Miyabayashi, Hideharu, Mohl, Wolfgang, Molnar, Martin, Moore, Gregory, Moran Faienzo, Gabriela, Morral, Eugeni Domenech, Motoya, Satoshi, Murali, Narayanachar, Mustaffa, Nazri Mohamad, Naem, Mohamed, Nakai, Katsuhiko, Nakajima, Koichi, Nakamoto, Yasunari, Nakamura, Masanao, Nancey, Stephane, Navaneethan, Udayakumar, Nawawi, Khairul Najmi Muhammad, Ninomiya, Tomoyuki, Novak, Janos, Oki, Motoji, Oliveira Santana, Genoile, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Parente, Jose Miguel, Patel, Kamal, Patel, Bhaktasharan, Pedersen, Peder, Petroniene, Rima, Petrov, Asen, Petrova, Elina, Piquet, Marie-astrid, Pokrotnieks, Juris, Poroshina, Elena, Portela, Francisco, Pruthi, Jatinder S., Prystupa, Lyudmila, Pukitis, Aldis, Qiu, Yun, Rafalsky, Vladimir, Rainis, Tova, Ramos Junior, Odery, Rashid, Mohammed, Rayyan, Yasser, Reshetko, Olga, Ribeiro, Tarsila, Rivero, Montserrat, Roblin, Xavier, Romatowski, Jacek, Rowbotham, David, Ruffinengo, Orlando Enrique, Rydzewska-wyszkowska, Grazyna, Sablin, Oleg, Sai, Souken, Saibeni, Simone, Said, Rosaida Hj. Md., Sakuraba, Hirotake, Samaan, Mark, Sandborn, William, Saruta, Masayuki, Sauk, Jenny, Savarino, Edoardo Vincenzo, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Seksik, Philippe, Senturk, Omer, Shelton, Edward, Shimizu, Masahito, Shin, Sungjae, Shukla, Richa, Sigal, Michael, Silva Junior, Roberto, Simoes Neto, Joaquim, Siroky Jr., Milan, Smajstrla, Vit, Smid, Vaclav, Smiley, Sarah, Soledad Brunatto, Luciana, Stanislavchuk, Mykola, Stokesberry, David, Stone, Christian, Suiter, Daniel, Suzuki, Takayoshi, Svorcan, Petar, Takagi, Sho, Takagi, Tomohisa, Takamura, Masaaki, Takayama, Tetsuji, Takeuchi, Ken, Tanaka, Akihito, Tanaka, Hiroki, Tanash, Omar, Tang, Wen, Tankova, Ludmila, Teixeira Campos, Luciana, Thin, Lena, Tkachev, Alexander, Tolmanis, Ivars, Tsarynna, Nataliia, Tsonev, Nikolay, Tulassay, Zsolt, Ueo, Tetsuya, Unal, Nalan, Valuyskikh, Ekaterina, Van Dop, Willemijn, Vasilevskaya, Olga, Venugopal, Kannan, Verstockt, Bram, Viamonte, Manuel, Vyshyvanyuk, Vira, Wang, Bangmao, Wang, Xiaoyan, Wang, Jiangbin, Wang, Yufang, Wei, Shu-chen, Weisshof, Roni, Wisam, Sbeit, Wojcik, Katarzyna, Yakovlev, Alexey, Yasuda, Hiroshi, Ye, Byongduk, Yen, Hsu-heng, Yilmaz, Hasan, Yokoyama, Yoko, Yoon, Hyuk, Yoshida, Takeshi, Yurkiv, Andriy, Zaha, Osamu, Zaltman, Cyrla, Zhan, Qiang, Zhang, Hongjie, Zhang, Shutian, Zhu, Lanxiang, Zou, Duowu, Zou, Xiaoping, and Zureikat, Firas

Abstract

Interleukin-23 inhibition is effective in treating ulcerative colitis. Guselkumab is a dual-acting, human IgG1, interleukin-23p19 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64. We aimed to evaluate the efficacy and safety of guselkumab as induction and maintenance therapy in patients with ulcerative colitis.

Published
2025
Full Text
View/download PDF

10. Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.

Author

Lichtenstein, Gary R.

Subjects
ADRENOCORTICAL hormones, ULCERATIVE colitis, DISEASE remission, TREATMENT effectiveness, TREATMENT duration, JANUS kinases, NEUROTRANSMITTER uptake inhibitors, TIME
Abstract

Upadacitinib was superior to placebo across clinical, endoscopic, and histologic endpoints; was effective in achieving corticosteroid-sparing treatment; and was well tolerated in the U-ACHIEVE maintenance study. In the U-ACTIVATE LTE trial, a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical program, corticosteroid-free and symptomatic remission was achieved with upadacitinib maintenance treatment and was maintained in more than 80% of patients through 48 weeks. Patients from the LTE study were further assessed up to 96 weeks. Most of these patients achieved and maintained corticosteroid-free CR, suggesting that upadacitinib continues to have a persistent benefit, is an excellent long-term treatment option for moderately to severely active UC, and can spare patients from corticosteroid use. [ABSTRACT FROM AUTHOR]

Published
2024

11. Efficacy, Safety and Immunogenicity of Subcutaneous Infliximab (CT-P13 SC) Monotherapy vs Combination Therapy With Immunosuppressants -- Post Hoc Analysis of LIBERTY-CD and LIBERTY-UC Studies.

Author

Lichtenstein, Gary R.

Subjects
IMMUNOGENETICS, COMBINATION drug therapy, PATIENT safety, IMMUNOSUPPRESSIVE agents, CROHN'S disease, ULCERATIVE colitis, TREATMENT effectiveness, DRUG efficacy, INFLIXIMAB, BIOSIMILARS, SUBCUTANEOUS injections
Abstract

Post hoc analysis of data from this prospective study found no significant difference in efficacy of therapy in patients who had a clinical response or patients on monotherapy or on immunosuppression at week 52 or 104. Although the rate of antidrug antibodies was lower with combination therapy, there was no difference in efficacy, biomarker profiles, or safety outcomes. If this study was conducted in a fashion similar to the SONIC trial, in which half of patients were prospectively randomized to monotherapy and half were given combination therapy, differences may have been observed, such as better outcomes in those on an immunomodulator and CT-P13 SC. [ABSTRACT FROM AUTHOR]

Published
2024

15. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Author

Peyrin-Biroulet, Laurent, primary, Allegretti, Jessica R., additional, Rubin, David T., additional, Bressler, Brian, additional, Germinaro, Matthew, additional, Huang, Kuan-Hsiang (Gary), additional, Shipitofsky, Nicole, additional, Zhang, Hongyan, additional, Wilson, Rebbecca, additional, Han, Chenglong, additional, Feagan, Brian G., additional, Sandborn, William J., additional, Panés, Julian, additional, Hisamatsu, Tadakazu, additional, Lichtenstein, Gary R., additional, Sands, Bruce E., additional, Dignass, Axel, additional, Abrahamovych, Orest, additional, Afanasieva, Halyna, additional, Aitova, Lilia, additional, Altintas, Engin, additional, Altwegg, Romain, additional, Andreev, Pavel, additional, Aomatsu, Kazuki, additional, Augustyn, Monika, additional, Balestrieri, Paola, additional, Begun, Jakob, additional, Brunatto, Luciana, additional, Bulgheroni, Diego, additional, Bunkova, Elena, additional, Cabello, Mercedes, additional, Cao, Qian, additional, Caprioli, Flavio, additional, Cerqueira, Rute, additional, Chen, Baili, additional, Chen, Chou-Chen, additional, Chen, Chou-Pin, additional, Chiu, Cheng-Tang, additional, Choi, Chang Hwan, additional, Cicala, Michele, additional, Datsenko, Olena, additional, Dewint, Pieter, additional, Domenech, Eugeni, additional, Dutré, Joris, additional, Duvall, George, additional, Fernandez, Juan, additional, Filip, Rafal, additional, Fogel, Ronald, additional, Fowler, Sharyle, additional, Fujii, Toshimitsu, additional, Fukata, Masayuki, additional, Furumoto, Yohei, additional, Gasbarrini, Antonio, additional, Gawdis-Wojnarska, Beata, additional, Gilletta, Cyrielle, additional, Gionchetti, Paolo, additional, Goldin, Eran, additional, Golovchenko, Oleksandr, additional, Gonciarz, Maciej, additional, Gonen, Can, additional, Segura, Gaston Gonzalez, additional, Gridnyev, Oleksii, additional, Gyokeres, Tibor, additional, Hébuterne, Xavier, additional, Hedin, Charlotte, additional, Hellström, Per, additional, Hilmi, Ida Normiha, additional, Horný, Ivo, additional, Horvat, Gyula, additional, Hoshi, Namiko, additional, Hrdlicka, Ludek, additional, Ishihara, Shunji, additional, Ivanishyn, Olha, additional, Jang, Byung Ik, additional, Junior, Odery, additional, Kagaya, Takashi, additional, Kanmura, Shuji, additional, Karakina, Marina, additional, Katsuhiko, Nakai, additional, Kierkus, Jaroslaw, additional, Kim, Hyo Jong, additional, Kim, Tae-Oh, additional, Kim, Young-Ho, additional, Kiss, Gyula G., additional, Klaus, Jochen, additional, Kleczkowski, Dariusz, additional, Klopocka, Maria, additional, Kobayashi, Taku, additional, Kobielusz-Gembala, Iwona, additional, Koo, Ja Seol, additional, Kopon, Adam, additional, Kravchenko, Tetiana, additional, Kudo, Masatoshi, additional, Kwon, Kwang An, additional, Lago, Paula, additional, Laharie, David, additional, Lawrance, Ian, additional, Leszczyszyn, Jaroslaw, additional, Li, Yan, additional, Lukas, Milan, additional, Maaser, Christian, additional, Maemoto, Atsuo, additional, Marusawa, Hiroyuki, additional, McBride, Matthew, additional, Mendu, Shoba, additional, Miheller, Pal, additional, Miyabayashi, Hideharu, additional, Mohl, Wolfgang, additional, Moore, Gregory, additional, Motoya, Satoshi, additional, Murali, Narayanachar, additional, Naem, Mohammed, additional, Nakajima, Koichi, additional, Nakamoto, Yasunari, additional, Nancey, Stéphane, additional, Neto, Joaquim, additional, Onizawa, Michio, additional, Ono, Yohei, additional, Osada, Taro, additional, Osipenko, Marina, additional, Owczarek, Danuta, additional, Patel, Bhaktasharan, additional, Patel, Kamal, additional, Petrova, Elina, additional, Poroshina, Elena, additional, Portela, Francisco, additional, Prystupa, Lyudmyla, additional, Rivero, Monserrat, additional, Roblin, Xavier, additional, Romatowski, Jacek, additional, Rydzewska, Grazyna, additional, Saibeni, Simone, additional, Sakuraba, Hirotake, additional, Samaan, Mark, additional, Schultz, Michael, additional, Schulze, Joerg, additional, Sedghi, Shahriar, additional, Seidler, Ursula, additional, Shin, Sung Jae, additional, Stanislavchuk, Mykola, additional, Stokesberry, David, additional, Suzuki, Takayoshi, additional, Taguchi, Hiroki, additional, Tankova, Lyudmila, additional, Thin, Lena, additional, Tkachev, Alexander, additional, Torrealba, Leyanira, additional, Tsarynna, Nataliia, additional, Tulassay, Zsolt, additional, Ueo, Tetsuya, additional, Valuyskikh, Ekaterina, additional, Vasilevskaya, Olga, additional, Viamonte, Manuel, additional, Wei, Shu-Chen, additional, Weisshof, Roni, additional, Wojcik, Katarzyna, additional, Ye, Byong Duk, additional, Yen, Hsu-Heng, additional, Yoon, Hyuk, additional, Yoshida, Kosuke, additional, Yurkiv, Andriy, additional, Zaha, Osamu, additional, and Zhan, Qiang, additional

Published
2023
Full Text
View/download PDF

16. S844 Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

Author

Lichtenstein, Gary R., primary, Dignass, Axel, additional, Rubin, David T., additional, Yarandi, Shadi, additional, Huang, Kuan-Hsiang G., additional, Germinaro, Matthew, additional, Miao, Ye, additional, Zhang, Hongyan, additional, Kierkuś, Jaroslaw, additional, Seidler, Ursula, additional, Maemoto, Atsuo, additional, Allegretti, Jessica R., additional, Bressler, Brian, additional, and Peyrin-Biroulet, Laurent, additional

Published
2023
Full Text
View/download PDF

17. S903 Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

Author

Rubin, David T., primary, Sands, Bruce E., additional, Lichtenstein, Gary R., additional, Baker, Thomas, additional, Huang, Kuan-Hsiang G., additional, Germinaro, Matthew, additional, Miao, Ye, additional, Zhang, Hongyan, additional, Nancey, Stéphane, additional, Allegretti, Jessica R., additional, Feagan, Brian G., additional, Hisamatsu, Tadakazu, additional, Panés, Julian, additional, Dignass, Axel, additional, Bressler, Brian, additional, and Peyrin-Biroulet, Laurent, additional

Published
2023
Full Text
View/download PDF

18. S1060 Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study

Author

Bressler, Brian, primary, Feagan, Brian G., additional, Panés, Julian, additional, Lichtenstein, Gary R., additional, Huang, Kuan-Hsiang G., additional, Germinaro, Matthew, additional, Pandya, Dwiti, additional, Han, Chenglong, additional, Miao, Ye, additional, Zhang, Hongyan, additional, Lateef, Syed, additional, Petroniene, Rima, additional, Rayyan, Yaser, additional, Peyrin-Biroulet, Laurent, additional, Rubin, David T., additional, and Hisamatsu, Tadakazu, additional

Published
2023
Full Text
View/download PDF

19. S907 Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

Author

Rubin, David T., primary, Panés, Julian, additional, Feagan, Brian G., additional, Yarandi, Shadi, additional, Huang, Kuan-Hsiang G., additional, Germinaro, Matthew, additional, Han, Chenglong, additional, Miao, Ye, additional, Zhang, Hongyan, additional, Qiu, Yun, additional, Klopocka, Maria, additional, Duvall, George, additional, Lichtenstein, Gary R., additional, Hisamatsu, Tadakazu, additional, Bressler, Brian, additional, and Peyrin-Biroulet, Laurent, additional

Published
2023
Full Text
View/download PDF

22. Colaboradores

Author

Abrams, Charles S., Adler, Ronald S., Agarwal, Anupam, Akin, Cem, Aksamit, Allen J., Jr., Al-Awqati, Qais, Allen, Upton D., Allos, Ban Mishu, Angus, Derek C., Appelbaum, Frederick R., Armitage, James O., Armstrong, April W., Armstrong, Deborah K., Arnaout, M. Amin, Arnold, Robert M., Aronson, Louise, Atkinson, John P., Attia, Evelyn, Auerbach, Andrew D., Ayanian, John Z., Baddour, Larry M., Baden, Lindsey R., Bailey, Thomas C., Bain, Barbara J., Bajorin, Dean F., Baloh, Robert W., Bangham, Charles R.M., Barasch, Jonathan, Barrett, Bruce, Bartholomew, John R., Bartleson, J.D., Barton, Mary B., Basner, Robert C., Bass, Adam J., Bass, Anne R., Bauman, Julie E., Bausch, Daniel G., Bayer, Arnold S., Bazarian, Jeffrey J., Bearman, Gonzalo M., Becker, Richard C., Beckham, J. David, Beckman, Joshua A., Beigel, John H., Bel, Elisabeth H., Belda, Walter, Jr., Benarroch, Eduardo E., Berger, Joseph R., Berliner, Nancy, Bernat, James L., Bessesen, Daniel H., Bibbins-Domingo, Kirsten, Biesecker, Leslie G., Biundo, Joseph J., Blankson, Joel N., Bloch, Karen C., Blom, Henk J., Boden, William E., Boivin, Guy, Bolognia, Jean, Bonomo, Robert A., Booth, Sarah L., Bosaeus, Ingvar G., Brenner, David J., Bridges, S. Louis, Jr., Brochard, Laurent, Brodsky, Robert A., Brook, Itzhak, Brown, Jennifer R., Brunetti, Enrico, Bryant, Amy E., Budge, Philip J., Buffet, Pierre A., Bushinsky, David A., Bykerk, Vivian P., Calabresi, Peter A., Calello, Diane P., Calfee, David P., Callahan, S. Todd, Camilleri, Michael, Canoso, Juan J., Cappellini, Maria Domenica, Carabello, Blase A., Carucci, Laura R., Castells, Mariana, Catherino, William H., Cederholm, Tommy E., Chalasani, Naga P., Chambers, Henry F., Chang, Larry W., Chang, Lin, Chao, Nelson J., Chatterjee, Mitali, Chaturvedi, Seemant, Chen, Lin H., Chen, Sharon C-A, Chon, Susan Y., Christiani, David C., Chu, Edward, Cieslak, Theodore J., Cioffi, George A., Clancy, Carolyn M., Clauss, Heather, Clauw, Daniel J., Clemmons, David R., Coffman, Thomas M., Cohen, David, Cohen, Jeffrey, Cohen, Myron S., Cohen, Steven P., Connors, Joseph M., Cook, Deborah J., Cook, Lucy B.M., Cooney, Kathleen A., Craigen, William J., Crandall, Jill P., Croft, Simon L., Crow, Mary K., Crump, John A., Cudkowicz, Merit E., Cunningham-Rundles, Charlotte, Dahir, Kathryn M., Damon, Inger K., Daras, Michael, Dart, Richard C., Davidson, Nancy E., Deane, Kevin D., DeAngelis, Lisa M., DeCamp, Malcolm M., DeLoughery, Thomas G., del Rio, Carlos, De Luca, Gabriele C., Denning, David W., Deuster, Patricia A., DeZern, Amy E., Dhatariya, Ketan K., Diasio, Robert B., Diemert, David J., Digre, Kathleen B., Dilsizian, Vasken, Dionne, Jodie A., Di Paola, Jorge, Dispenzieri, Angela, Dogra, Sunil, Doroshow, James H., Douglas, John M., Jr., Drazen, Jeffrey M., Drekonja, Dimitri, Dubberke, Erik R., DuBeau, Catherine E., Dumler, J. Stephen, Duvic, Madeleine, Ebi, Kristie, Edwards, Kathryn M., Edwards, N. Lawrence, Eikelboom, John W., Einhorn, Lawrence H., Elliott, Perry M., Emanuel, Ezekiel J., Falagas, Matthew E., Falk, Gary W., Fang, James C., Farley, Monica M., Feder, Gene, Feller-Kopman, David J., File, Thomas McDonald, Jr., Fishman, Glenn I., Flack, John M., Fleckenstein, James M., Fleisher, Lee A., Flint, Paul W., Fogel, Evan L., Fontana, Robert J., Forsmark, Chris E., Fournier, Pierre-Edouard, Fowler, Vance G., Jr., Franco, Manuel A., Fraser, Victoria J., Freeman, Roy, Freund, Karen M., Froberg, Blake A., Gallagher, Patrick G., Gandhi, Monica, Gandhi, Rajesh T., Ganz, Leonard, Garan, Hasan, Garcia-Tsao, Guadalupe, Geisler, William M., Gelfand, Joel M., George, Tony P., Gepstein, Lior, Gertz, Morie A., Ghanem, Khalil G., Gharavi, Ali G., Ghossein, Cybele, Gill, Christopher J., Ginsburg, Geoffrey S., Glesby, Marshall J., Gnann, John W., Jr., Goldman, David L., Goldman, Lee, Goldstein, Larry B., Gordon, Anthony C., Gotlib, Jason, Gotuzzo, Eduardo, Grasemann, Hartmut, Green-McKenzie, Judith, Greenberg, Harry B., Greenberg, Steven A., Greer, David M., Greysen, S. Ryan, Griffin, Marie R., Griggs, Robert C., Grossman, Daniel, Guay-Woodford, Lisa M., Gulick, Roy M., Haake, David A., Hagman, Melissa M., Hagspiel, Klaus D., Harris, Raymond C., Havers, Fiona P., Heath, Elisabeth I., Hecht, Frederick M., Hensrud, Donald D., Hess, Jeremy, Hewlett, Erik L., Hift, Richard J., Hill, David R., Hill, Nicholas S., Hillyer, Christopher D., Hirsch, Hans H., Hoeper, Marius M., Hoit, Brian D., Holers, V. Michael, Holland, Steven M., Hollenberg, Anthony N., Hollenberg, Steven M., Howard, Jo, Hunter, David J., Hussain, Khalid, Iannuzzi, Michael C., Inman, Robert D., Inouye, Sharon K., Ison, Michael G., Jen, Joanna C., Jensen, Dennis M., Jensen, Michael D., Jensen, Robert T., Johnston, S. Claiborne, Jones, Robin L., Jordan, Richard C., Kahi, Charles J., Kaiser, Laurent, Kaminski, Henry J., Kamya, Moses R., Kao, Louise W., Kaplan, Steven A., Kastner, Daniel L., Katzka, David A., Katzman, Debra K., Kaushansky, Kenneth, Kaye, Keith S., Keating, Armand, Kelley, Robin K., Kennedy, Richard B., Khuri, Fadlo R., Kim, Rose, Kirchhoff, Louis V., Kirking, Hannah, Kirtane, Ajay J., Kishnani, Priya S., Klausner, Jeffrey D., Klion, Amy D., Klompas, Michael, Knopman, David S., Ko, Christine J., Kodali, Susheel, Kontoyiannis, Dimitrios P., Koppel, Barbara S., Korenblat, Kevin M., Korf, Bruce R., Kortepeter, Mark G., Koshy, Anita A., Kottilil, Shyamasundaran, Kovacs, Joseph A., Kovacs, Thomas O., Kowdley, Kris V., Kraft, Monica, Kramer, Christopher M., Krasnewich, Donna M., Kraus, William E., Krause, Peter J., Kroger, Andrew T., Kroshinsky, Daniela, Kuemmerle, John F., Kuipers, Ernst J., Kutner, Jean S., Laheru, Daniel, Lampert, Rachel, Landefeld, C. Seth, Landovitz, Raphael J., Landry, Donald W., Lange, Richard A., Lee, Hochang B., Lee, Nelson, Levey, Andrew S., Levine, Stephanie M., Lichtenstein, Gary R., Liebmann, Jeffrey M., Liebschutz, Jane M., Lim, Henry W., Lima, Aldo A.M., Limaye, Ajit P., Limdi, Nita A., Link, Mark S., Liu, Catherine, Lloyd-Jones, Donald M., Lopez, Fred A., Louie, Arnold, Lyness, Jeffrey M., MacKenzie, C. Ronald, MacLennan, Calman A., MacMillan, Harriet L., Madoff, Robert D., Maher, Jacquelyn, Maier, Lisa A., Maldarelli, Frank, Malhotra, Atul, Manary, Mark J., Marcos, Luis A., Marelli, Ariane J., Marks, Andrew R., Marschall, Jonas, Martin, Paul, Martinez, Fernando J., Mason, Joel B., Masur, Henry, Mathers, Amy J., Matthay, Michael A., McCool, F. Dennis, McInnes, Iain B., McLaughlin, Vallerie, McMichael, Amy, McMurray, John J.V., McQuaid, Kenneth R., Mead, Paul S., Means, Robert T., Jr., Melia, Michael T., Mellinghoff, Ingo K., Melton, Genevieve B., Merrick, Samuel T., Miceli, Marisa H., Michel, Marc, Mokdad, Ali H., Moy, Ernest, Mukherjee, Debabrata, Murr, Andrew H., Myerburg, Robert J., Nadeau, Kari C., Nath, Avindra, Neal-Perry, Genevieve, Neilson, Eric G., Nelson, Christina A., Nelson, David B., Nelson, Lewis S., Nestler, Eric J., Neuzil, Kathleen M., Nieman, Lynnette K., Niven, Alexander S., O’Connor, Christopher M., O’Connor, Francis G., O’Connor, Patrick G., O’Donnell, Anne E., O’Donnell, James S., Oh, Jae K., Okun, Michael S., O’Leary, Sean T., Olgin, Jeffrey E., Olivier, Kenneth N., Olivotto, Iacopo, Olsen, Nancy J., Orenstein, Walter A., Ortel, Thomas L., O’Shea, John J., Osmon, Douglas R., Ostrem, Jill L., Ostrosky-Zeichner, Luis, Otto, Catherine M., Ottolini, Martin G., Ovsyannikova, Inna G., Pappas, Peter G., Park, Ben Ho, Patel, Robin, Patterson, Thomas F., Pawlotsky, Jean-Michel, Payne, Thomas H., Pearce, Elizabeth N., Pearson, Richard D., Perl, Trish M., Petersen, Brett W., Petri, William A., Jr., Pfeffer, Marc A., Philips, Jennifer A., Pisetsky, David S., Pletcher, Steven D., Plumb, Ian D., Poland, Gregory A., Powell, Frank, Pyeritz, Reed E., Quinn, Thomas C., Racaniello, Vincent, Radhakrishnan, Jai, Radich, Jerald, Rafailidis, Petros I., Raghu, Ganesh, Ragni, Margaret V., Rahman, Proton, Rajkumar, S. Vincent, Ralston, Stuart H., Raoult, Didier, Reboli, Annette C., Reddy, K. Rajender, Redelmeier, Donald A., Redlich, Carrie A., Reilly, John, Reller, Megan E., Reno, Hilary E.L., Resnick, Neil M., Rice, Louis B., Roach, E. Steve, Robinson, Jennifer G., Rogatsky, Inez, Rogers, Joseph G., Rolain, Jean-Marc, Rollins, Barrett J., Romero, José R., Rosen, Jennifer B., Rosenthal, Philip J., Russell, James A., Rustgi, Anil K., Safer, Joshua D., Saini, Sarbjit S., Salmon, Jane E., Salvana, Edsel Maurice T., Santoro, Nanette, Santucci, Peter A., Sarnak, Mark J., Savage, Kerry J., Savard, Patrice, Sawka, Michael N., Scanlon, Paul D., Schafer, Andrew I., Schiff, Manuel, Schilsky, Michael L., Schneider, Thomas Rudolf, Schooley, Robert T., Schriger, David L., Schuchter, Lynn M., Schwartz, Lawrence B., Seas, Carlos, Seifert, Steven A., Seifter, Julian Lawrence, Selcen, Duygu, Selim, Magdy, Semrad, Carol E., Sepulveda, Jorge, Shaw, Pamela J., Shaz, Beth H., Sheridan, Robert L., Sherman, Stuart, Shojania, Kaveh G., Shopsin, Bo, Shy, Michael E., Sidransky, Ellen, Sifri, Costi D., Siliciano, Robert F., Simel, David L., Skorecki, Karl, Slawski, Barbara A., Slutsky, Arthur S., Smetana, Gerald W., Smith, A. Gordon, Smith, Stephen R., Southwick, Frederick S., Spiegel, Allen M., Spiera, Robert, Spinola, Stanley M., Spong, Catherine Y., Stabler, Sally P., Stark, Paul, Clair, E. William St., Steiner, Theodore S., Stephens, David S., Stevens, David A., Stevens, Dennis L., Stokes, M. Barry, Stoller, James K., Stone, John H., Stone, Richard M., Su, Edwin P., Swerdloff, Ronald S., Swygard, Heidi, Sykes, Megan, Talbot, H. Keipp, Tamimi, Rulla M., Tanofsky-Kraff, Marian, Tarlo, Susan M., Taylor, Stephanie N., Teirstein, Paul S., Telford, Sam R., III, Thakker, Rajesh V., Therrien, Judith, Thompson, George R., III, Tormoehlen, Laura, Tosti, Antonella, Trehan, Indi, Umpierrez, Guillermo E., Valeri, Anthony Michael, Varga, John, Vaughn, Bradley V., Venook, Alan P., Verbalis, Joseph G., Vose, Julie M., Wachter, Robert M., Walsh, B. Timothy, Walsh, Edward E., Walsh, Thomas J., Walston, Jeremy D., Walter, Roland B., Wang, Christina, Wang, Kenneth K., Ware, Lorraine B., Warren, Cirle A., Watkins, Paul B., Weber, Thomas J., Weimer, Louis H., Weinberg, Geoffrey A., Weinstein, Robert S., Weiss, Roger D., Weiss, Roy E., Weitz, Jeffrey I., Welt, Frederick G.P., Wenzel, Richard P., Werth, Victoria P., West, Sterling G., White, A. Clinton, Jr., White, Christopher J., White, Julian, White, Perrin C., Whitley, Richard J., Whyte, Michael P., Wiebe, Samuel, Wiener-Kronish, Jeanine P., Wilber, David J., Wilcox, Mark H., Winikoff, Beverly, Winter, Jane N., Wittink, Marsha N., Wolff, Tracy A., Wolin, Edward M., Wormser, Gary P., Yancy, Clyde W., Young, Neal S., Young, Vincent B., Young, William F., Jr., Yu, Alan S.L., Zimetbaum, Peter, and Zucker, Jane R.

Published
2025
Full Text
View/download PDF

25. Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study.

Author

Lichtenstein, Gary R.

Subjects
DISEASE duration, ULCERATIVE colitis, DISEASE remission, TREATMENT effectiveness, MONOCLONAL antibodies, DRUG efficacy, ENDOSCOPIC gastrointestinal surgery, EVALUATION
Abstract

A benefit with risankizumab compared with placebo was observed in patients with an inadequate response to prior nonadvanced therapy (29.7% vs 8.4%) and in patients with an inadequate response to prior advanced therapy (11.4% vs 4.3%). In this study, there were several important findings: (1) the proportion of patients who had prior failure to advanced therapy was numerically higher for patients who did not achieve CR or EI at maintenance week 0 than for those who achieved it; (2) the rates of each clinical, endoscopic, and histologic outcome were generally numerically higher with risankizumab vs placebo regardless of CR or EI status at maintenance week 52; and (3) among patients with clinical response to the induction treatment who did not achieve CR or EI, risankizumab 360 mg SC demonstrated numerically higher rates of improvement in all presented outcomes over risankizumab 180 mg SC at maintenance week 52. This study highlights that exposure to risankizumab was associated with improved outcome regardless of week 12 (early) outcomes. [ABSTRACT FROM AUTHOR]

Published
2024

26. Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With Up to 3 Years of Treatment.

Author

Lichtenstein, Gary R.

Subjects
THERAPEUTIC use of monoclonal antibodies, ULCERATIVE colitis, SEVERITY of illness index, DISEASE remission, DRUG efficacy, ENDOSCOPIC gastrointestinal surgery, QUALITY of life, HISTOLOGY
Abstract

This study demonstrated that mirikizumab maintained endoscopic and histologic outcomes through an additional 2 years of continuous treatment for a total of 3 years. In addition, individuals who achieved long-term durable and sustained endoscopic and histologic outcomes with mirikizumab had in aggregate achieved an overall better health-related QOL. Remarkably, nearly three-quarters (70%) of patients who achieved CR at week 52 were able to achieve histologic and endoscopic remission without neutrophils on histology at week 152, and nearly half (47%) of all clinical remitters at week 52 were able to achieve endoscopic normalization at week 152. [ABSTRACT FROM AUTHOR]

Published
2024

27. The Efficacy of Maintenance Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase Inhibitor History.

Author

Lichtenstein, Gary R.

Subjects
THERAPEUTIC use of monoclonal antibodies, PATIENT safety, ULCERATIVE colitis, SEVERITY of illness index, JANUS kinases, MONOCLONAL antibodies, DRUG efficacy, NEUROTRANSMITTER uptake inhibitors
Abstract

It is recognized that individuals with prior exposure to anti-tumor necrosis factor (TNF) drugs often have a lower chance of success with subsequent anti-TNF therapies (ie, the effectiveness may be reduced and patients may be less likely to achieve remission or may require switching to a different medication class altogether). Similar findings have been seen with S1P receptor modulators. This study evaluated pooled induction data from 4 randomized controlled trials (1562 patients) and related that S1P receptor modulators may be more effective in inducing CR compared with placebo in patients with moderately to severely active UC and prior biologic exposure. The same finding has been seen in UC patients with prior biologic use who initiate JAK inhibitor therapy, whereas the GEMINI trials have shown that vedolizumab is more effective in patients who have not previously received anti-TNF medications compared with patients with prior failure of anti-TNF therapy. [ABSTRACT FROM AUTHOR]

Published
2024

28. Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension.

Author

Lichtenstein, Gary R.

Subjects
INFECTION risk factors, THERAPEUTIC use of monoclonal antibodies, PATIENT safety, DRUG side effects, CLINICAL trials, TERMINATION of treatment, ULCERATIVE colitis, TREATMENT effectiveness, SPHINGOSINE-1-phosphate, DRUG efficacy, INFLIXIMAB, CELL receptors, DRUG tolerance
Abstract

In the True North Study, which assessed ozanimod vs placebo, it is comforting to see that no new safety concerns were identified. A significant number of patients (43%) persisted on medication for up to 5 years. The rate of treatment discontinuation owing to AEs was low. With 2681 PY of follow-up, the study has not yet achieved adequate power to assess for the presence of uncommon events such as lymphoma. Continued follow-up will be necessary. [ABSTRACT FROM AUTHOR]

Published
2024

29. Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study.

Author

Lichtenstein, Gary R.

Subjects
ANTI-inflammatory agents, ANTIULCER drugs, ULCERATIVE colitis, TREATMENT effectiveness, SEVERITY of illness index, MONOCLONAL antibodies, ENDOSCOPIC gastrointestinal surgery, HISTOLOGY
Abstract

Clinically meaningful improvements in endoscopic and histologic outcomes compared with placebo (guselkumab withdrawal) were notably present in both the biologic/JAK inhibitor--naive patient subpopulation and also in the patients who had an inadequate response or intolerance to biologics and/or JAK inhibitors. As expected, patients who received placebo after responding to initial therapy had progressive worsening of histologic and combined histologic and endoscopic outcomes. The findings of this study have important clinical implications for patient care. [ABSTRACT FROM AUTHOR]

Published
2024

30. Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.

Author

Lichtenstein, Gary R.

Subjects
THERAPEUTIC use of monoclonal antibodies, ADRENOCORTICAL hormones, ULCERATIVE colitis, SEVERITY of illness index, TREATMENT effectiveness, ORAL drug administration, MONOCLONAL antibodies
Abstract

In the QUASAR phase 3 induction trial, guselkumab was demonstrated to be effective for achieving CR in patients with moderately to severely active UC. In the QUASAR randomized withdrawal maintenance study, 50.0% (P<.001) of patients with moderately to severely active UC receiving SC guselkumab 200 mg every 4 weeks and 45.2% (P<.001) of patients receiving SC guselkumab 100 mg every 8 weeks achieved the primary endpoint of CR at week 44 compared with placebo (18.9%). Among patients with moderately to severely active UC who were receiving concomitant oral corticosteroids at maintenance baseline, the majority of guselkumab-treated patients eliminated corticosteroids within 8 weeks. These impressive and clinically relevant findings highlight the fact that patients who were receiving maintenance treatment with guselkumab who achieved CR at week 44 did so without concomitant use of oral corticosteroids. [ABSTRACT FROM AUTHOR]

Published
2024

31. Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study.

Author

Lichtenstein, Gary R.

Subjects
ANTI-inflammatory agents, ANTIULCER drugs, PATIENT safety, ULCERATIVE colitis, TREATMENT effectiveness, SEVERITY of illness index, MONOCLONAL antibodies, DRUG efficacy
Abstract

Of the patients who did not initially respond to 3 induction doses, 60.6% (123 of 203) achieved clinical response to 3 further doses and entered the maintenance study phase. This more refractory population of UC patients (who did not respond initially by week 12 but did respond after 3 further doses of guselkumab 200 mg SC at weeks 12, 16, and 20) had higher UC disease burden and were able to maintain or improve endoscopic, histologic, symptomatic, and QOL outcomes. Safety results were consistent with the overall population and safety profile of guselkumab in its approved indications. Overall, the results support continuing guselkumab treatment in this more refractory patient population. [ABSTRACT FROM AUTHOR]

Published
2024

35. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

Author

Lichtenstein, Gary R, primary, Bressler, Brian, additional, Francisconi, Carlos, additional, Vermeire, Severine, additional, Lawendy, Nervin, additional, Salese, Leonardo, additional, Sawyerr, Gosford, additional, Shi, Hongjiong, additional, Su, Chinyu, additional, Judd, Donna T, additional, Jones, Thomas, additional, and Loftus, Edward V, additional

Published
2022
Full Text
View/download PDF

36. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary

Author

Shubow, Sophie, primary, Sun, Qin, additional, Nguyen Phan, Ai Len, additional, Hammell, Dana C., additional, Kane, Maureen, additional, Lyman, Gary H., additional, Gibofsky, Allan, additional, Lichtenstein, Gary R., additional, Bloomgarden, Zachary, additional, Cross, Raymond K., additional, Yim, Sarah, additional, Polli, James E., additional, and Wang, Yow‐Ming, additional

Published
2022
Full Text
View/download PDF

40. Tu1480: EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS PATIENTS WITH EXTRAINTESTINAL MANIFESTATIONS IN OCTAVE OPEN

Author

Rubin, David T., primary, Vavricka, Stephan R., additional, Armuzzi, Alessandro, additional, Dubinsky, Marla C., additional, Sharara, Ala I., additional, Modesto, Irene, additional, Fellmann, Marc, additional, Liguori, Giuseppina, additional, Lawendy, Nervin, additional, Cadatal, Mary Jane, additional, and Lichtenstein, Gary R., additional

Published
2022
Full Text
View/download PDF

41. Tu1446: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12

Author

Allegretti, Jessica R., primary, Rubin, David T., additional, Bressler, Brian, additional, Huang, Kuan-Hsiang G., additional, Shipitofsky, Nicole, additional, Germinaro, Matthew, additional, Zhang, Hongyan, additional, Johanns, Jewel, additional, Feagan, Brian G., additional, Sandborn, William J., additional, Sands, Bruce E., additional, Hisamatsu, Tadakazu, additional, Lichtenstein, Gary R., additional, Panés, Julian, additional, and Dignass, Axel, additional

Published
2022
Full Text
View/download PDF

42. 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Author

Long, Millie D., primary, Cross, Raymond K., additional, Lichtenstein, Gary R., additional, Calkwood, Jonathan, additional, Pai, Ashwini, additional, Pondel, Marc, additional, Ahmad, Harris, additional, Charles, Lorna, additional, Elegbe, Ayanbola, additional, Petersen, AnnKatrin, additional, Sheffield, James K., additional, Javed, Adil, additional, Hou, Jason K., additional, Regueiro, Miguel D., additional, Wolf, Douglas C., additional, and Armuzzi, Alessandro, additional

Published
2022
Full Text
View/download PDF

44. Su1860 GUSELKUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY PROMIS-29 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY

Author

Panés, Julián, Dignass, Axel, Lichtenstein, Gary R., Huang, Kuan-Hsiang G., Germinaro, Matthew, Houck, Nicole, Han, Chenglong, Miao, Ye, Zhang, Hongyan, Farsakh, Niazy A. Abu, Patel, Bhaktasharan, Owczarek, Danuta, Hisamatsu, Tadakazu, Sands, Bruce E., and Bressler, Brian

Published
2024
Full Text
View/download PDF

46. Su1809 ASSESSMENT OF STEROID USE IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS WHO INITIATED A NEW JANUS KINASE INHIBITOR OR TUMOR NECROSIS FACTOR INHIBITOR USING DATA FROM A UNITED STATES CLAIMS DATABASE

Author

Dubinsky, Marla C., Gianfrancesco, Milena, Gauthier, Genevieve, Fallon, Lara, Lichtenstein, Gary R., Khan, Nabeel H., Melmed, Gil, Hanauer, Stephen B., Ritter, Timothy, Bell, Griffith, Lee, Yi-Chien, Kulisek, Nicole, Yndestad, Arne, and Rubin, David T.

Published
2024
Full Text
View/download PDF

48. 759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY

Author

Rubin, David T., Allegretti, Jessica R., Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi, Huang, Kuan-Hsiang G., Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Feagan, Brian G., Hisamatsu, Tadakazu, Lichtenstein, Gary R., Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E., and Dignass, Axel

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results